banner
 
bar

program

slides
bar
 
 

Understanding and Applying New Advances in Basal Insulin Therapy

WebCAST

pre-program survey
We Invite You to Take a Moment and Complete This
Pre-Program Knowledge and Clinical Performance Survey.
Thank You

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Estimated Time to Complete Educational Activity

2.5 hours

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in diabetes management.

Release Date

June 10, 2015

Expiration Date

June 10, 2017

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period June 10, 2015 through June 10, 2017, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 8 segments totaling 2.5 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.

Registration

Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

Supported by an educational grant from SANOFI Diabetes

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Other Credits

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Program Faculty and Disclosure

JUAN P. FRIAS, MD, FACE
(Program Chair)
Assistant Professor of Medicine
University of California, San Diego
President
National Research Institute
Los Angeles, CA

Consultant: Johnson & Johnson, CeQur
Grant/Research Support: AbbVie, Ayapaneco, BMS, Lilly, Roche, Janssen,
Merck, Novo Nordisk, Sanofi, Pfizer,
Boehringer Ingelheim



CHARLES F. SHAEFER Jr., MD, FACP
Assistant Clinical Professor of Medicine
Medical College of Georgia
Senior Partner/Attending Physician
University Medical Group
Augusta, GA

Consultant: Sanofi - US and Global, Lilly - US and Global,
BI, AZ, Janssen
Speaker’s Bureau: Sanofi, Lilly, BI, AZ, Janssen


PABLO F. MORA, MD, MSc, FACE, CDE
Clinical Associate Professor
University of Texas Southwestern Medical Center
Staff Endocrinologist
Diabetes America
Dallas, TX

Consultant and Speaker’s Bureau: Novo Nordisk

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.
Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Determine when new formulations of long-acting basal insulin therapy should be employed in patients on pre-existing oral therapy and/or those on established basal insulin who are at risk for or who a history of hypglycemia;
  • Develop a deeper, more clinically relevant understanding of the comparative features—pharmacodynamics, injection devices, efficacy, safety, side effects (hypoglycemia), and patient acceptance—among established and investigational and/or newly developed, long-acting basal insulin formulations;
  • Apply guidelines, strategies, drug selection strategies, and recommendations endorsed by the Year 2012 ADA/EASD Position Statement on glycemic management of T2D, to the front lines of internal medicine and primary care practice;
  • Determine when basal insulin therapy should be intensified or combined with other agents; and, more select among basal insulin-based options to ensure optimal control of HA1c and reduction of hypoglycemic risk with insulin-based treatment;
  • Select and discriminate among basal insulin analogues, including longer-acting formulations in development or that have recently become available for clinical use, based on pharmacodynamic profiles, and as a result, align basal insulin therapy with specific patient profiles and needs;

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2015 by CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC

 
6

 

Key Program Topics Include:

A1c
AACE
AACE/ACE
ACCORD
ADA
ADA/EASD
ADVANCE
Alpha glucosidase inhibitors
Amylin mimetics
Antihyperglycemic
Basal Insulin
biguanides
Biguanides
Bile acid sequentrants
Dapagliflozin
DCCT
Diabetes

Dopamine 2 agonists
DPP-4 inhibitor
DPP4 inhibitors
Dyslipidemia
ESRD
Exenatide
FPG
Glargine
Gliclazide
glimiperide
Glomerulus
GLP agonist
GLP1 receptor agonists
Glucose
GLUT2
glyburide
Glycemia
Glycemic
Glycogenolysis

 

GRADE
HbA1c
HDL
Homeostasis
SGLT2
Hypertension
Hypoglycemia
Hypoglycemia
incretin
Insulin
Insulin detemir
insulinopenia
Kidney
LDL
Meglitines
Metformin
Microalbumin
NHANES
NPH

Obesity
Type 2
Pioglitazone
PPG
prandial
PREMIX
PROACTIVE
SGLT1
Sodium-Glucose Cotransporters
Sulfonlyureas
Sulfonylureas
T2D
T2DM
Thiazolidinedione
troglitazone
TZD
UKPDS
VADT